The Valley Desk

Clinical trial reportThe oncologistPublished

Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Fox Chase Cancer Center, Jefferson Health, Thomas Jefferson University, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Clinical trial report
Venue
The oncologist
Published
Subject terms
Esophagogastric Junction; Humans; Esophageal Neoplasms; Stomach Neoplasms; Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal, Humanized; Esophageal; Insulin-like growth factor-1 receptor; Gastroesophageal Junction; Xixutumumab
PubMed ID
37104870
PubMed Central ID
PMC10485278
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal